KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Operating Leases (2018 - 2025)

Moderna (MRNA) has disclosed Operating Leases for 7 consecutive years, with $682.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Operating Leases changed N/A to $682.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $682.0 million, a N/A change, with the full-year FY2022 number at $92.0 million, changed N/A from a year prior.
  • Operating Leases was $682.0 million for Q2 2025 at Moderna, up from $667.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $697.0 million in Q3 2023 to a low of $92.0 million in Q4 2022.
  • A 5-year average of $392.9 million and a median of $396.0 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: rose 1.27% in 2021, then fell 2.58% in 2024.
  • Moderna's Operating Leases stood at $105.0 million in 2021, then decreased by 12.38% to $92.0 million in 2022, then surged by 657.61% to $697.0 million in 2023, then fell by 2.58% to $679.0 million in 2024, then grew by 0.44% to $682.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Operating Leases are $682.0 million (Q2 2025), $667.0 million (Q1 2025), and $679.0 million (Q3 2024).